Learn More, Access Our New Resources and Take Action! This month, we’re supporting the 26.8 million people in the U.S. living ...

How one man, along with his care team, turned an all-consuming cancer diagnosis into a management strategy with inspiration ...

Dr. Suresh S. Ramalingam explains that patients with stage 3 lung cancer who undergo chemotherapy and radiation may develop ...

The first patient was dosed in the SKYBRIDGE study assessing peluntamig with Tecentriq for advanced small cell lung cancer ...

Oct. 9, 2024 — Researchers have demonstrated that patients with metastatic non-squamous non-small cell lung cancer (NSCLC) harboring specific mutations in the STK11 and/or KEAP1 tumor suppressor ...

These symptoms require immediate medical care ... One clinical trial of Opdivo involved adults with squamous non-small cell lung cancer (NSCLC). Researchers found that people with squamous NSCLC ...

Helene Duhamel was recently diagnosed with non-small cell squamous cell lung cancer. Duhamel shares her thoughts on her ...

Research Pinpoints Weakness in Lung Cancer's Defenses Feb. 10, 2025 — Scientists uncover an enzyme that boosts cancer cell metabolism ... the disease even before symptoms occur.

Tarlatamab is a bispecific T-cell engager that binds to DLL3 expressed on the surface of tumor cells and CD3 expressed on the surface of T-cells.

A groundbreaking new urine test could soon help spot the early warning signs of lung cancer long before symptoms appear.

Non-small-cell lung cancer (NSCLC) is the most common type of cancer affecting the lungs. The diverse types of NSCLC are characterized by cancer cells that grow and spread in different ways.

Results showed tarlatamab demonstrated statistically significant and clinically meaningful improvement in overall survival vs standard of care therapy. Topline data were announced from a phase 3 ...